PubRank
Search
About
Myron Schwartz
Author PubWeight™ 162.88
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med
2008
54.30
2
Design and endpoints of clinical trials in hepatocellular carcinoma.
J Natl Cancer Inst
2008
11.27
3
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
N Engl J Med
2008
9.20
4
Resection of hepatocellular cancer ≤2 cm: results from two Western centers.
Hepatology
2013
5.05
5
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis
2005
4.51
6
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Gastroenterology
2009
4.50
7
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Cancer Res
2008
4.35
8
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology
2008
4.03
9
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.
Hepatology
2007
3.85
10
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.
Cancer Res
2009
3.18
11
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
J Hepatol
2009
2.42
12
Gene-expression signature of vascular invasion in hepatocellular carcinoma.
J Hepatol
2011
2.39
13
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Gastroenterology
2006
2.32
14
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma.
Hepatology
2004
2.29
15
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.
Am J Gastroenterol
2003
2.18
16
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
J Hepatol
2006
1.98
17
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.
Gastroenterology
2011
1.77
18
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
J Hepatol
2010
1.66
19
Resection of hepatocellular carcinoma with macroscopic vascular invasion.
Ann Surg Oncol
2013
1.65
20
Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis.
Ann Surg
2015
1.53
21
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
Lancet Oncol
2002
1.52
22
Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation.
Hepatology
2009
1.48
23
The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis.
Transpl Int
2010
1.48
24
Intrahepatic cholangiocarcinoma: new insights in pathology.
Semin Liver Dis
2011
1.46
25
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature.
Dig Dis Sci
2006
1.45
26
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor.
Liver Transpl
2004
1.44
27
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Clin Cancer Res
2012
1.44
28
Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video).
Gastrointest Endosc
2012
1.09
29
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.
J Clin Invest
2012
1.09
30
Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor.
Cardiovasc Pathol
2008
1.09
31
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.
Liver Transpl
2009
1.02
32
Second hepatic resection for recurrent hepatocellular cancer: a Western experience.
J Hepatol
2010
1.00
33
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
Oncologist
2005
0.96
34
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
PLoS One
2012
0.95
35
Liver transplantation for neuroendocrine tumors.
J Gastrointest Surg
2004
0.93
36
Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation.
Am J Transplant
2004
0.91
37
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
Target Oncol
2013
0.91
38
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction.
Semin Liver Dis
2011
0.91
39
Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor?
Liver Transpl
2005
0.90
40
The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation.
Clin Transplant
2004
0.88
41
Trefoil factor-3 expression in human colon cancer liver metastasis.
Clin Exp Metastasis
2008
0.87
42
Resection of hepatocellular carcinoma without cirrhosis.
Ann Surg
2012
0.87
43
Treatment strategies for hepatocellular carcinoma in cirrhosis.
J Gastrointest Surg
2003
0.87
44
Retracted
Liver functional reserve estimation: state of the art and relevance to local treatments.
Oncology
2010
0.86
45
Establishing an international training program for surgical residents.
J Surg Educ
2007
0.85
46
Primary hepatic signet ring cell neuroendocrine tumor: a case report with literature review.
Semin Liver Dis
2010
0.84
47
Cancer history and other personal factors affect quality of life in patients with hepatitis C.
Health Qual Life Outcomes
2005
0.84
48
Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms.
Am J Surg Pathol
2012
0.83
49
Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective.
J Hepatobiliary Pancreat Sci
2009
0.83
50
Epstein-Barr virus and human hepatocellular carcinoma.
Cancer Lett
2003
0.82
51
Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Liver Transpl
2011
0.82
52
Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors.
Pancreas
2011
0.82
53
Adult-adult living donor liver transplantation.
J Gastrointest Surg
2004
0.82
54
Liver transplantation for hepatocellular carcinoma.
Hepatol Res
2007
0.81
55
Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there.
Semin Liver Dis
2006
0.81
56
Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma.
Liver Transpl
2008
0.81
57
The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer.
Int J Gynecol Cancer
2014
0.81
58
Hand-assisted laparoscopic donor hepatectomy for living related transplantation in the porcine model.
Surg Laparosc Endosc Percutan Tech
2002
0.80
59
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
J Surg Oncol
2014
0.79
60
Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis.
Semin Liver Dis
2008
0.77
61
Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis.
HPB (Oxford)
2012
0.77
62
Changing epidemiology of hepatocellular adenoma in the United States: review of the literature.
Int J Hepatol
2013
0.77
63
Unresectable squamous cell carcinoma of donor origin treated with immunosuppression withdrawal and liver retransplantation.
Am J Transplant
2004
0.76
64
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Pancreas
2016
0.75
65
Outcomes in hepatitis B transplant candidates with or without hepatocellular carcinoma: UNOS policy vindicated!
Liver Transpl
2007
0.75
66
Surgical treatment of hepatocellular cancer: expert consensus conference.
HPB (Oxford)
2010
0.75
67
Reply:.
Hepatology
2013
0.75
68
Survey of health needs and concerns of rural Pennsylvanians.
J Agromedicine
2005
0.75
69
The financial impact of interim and prospective payment systems on home health providers in rural communities.
J Health Care Poor Underserved
2005
0.75
70
HazDat in action.
Occup Health Saf
2006
0.75